Please login to the form below

Not currently logged in
Email:
Password:

LMTX

This page shows the latest LMTX news and features for those working in and with pharma, biotech and healthcare.

AbbVie takes anti-tau drug into phase II for Alzheimer's

AbbVie takes anti-tau drug into phase II for Alzheimer's

Whether tau-targeting drugs can do better remains to be seen. Last year, TauRx's tau aggregation inhibitor LMTX failed to slow cognitive decline in three phase III trials - two in

Latest news

  • Tau protein drug fails late-stage trial Tau protein drug fails late-stage trial

    LMTX is thought to reduce the accumulation of the tau protein, which normally stabilizes neurons, into potentially toxic tangles. ... The LMTX data were presented at the Alzheimer's Association International Conference in Toronto.

  • Funding boost for late-stage tau-based Alzheimer’s research Funding boost for late-stage tau-based Alzheimer’s research

    Funding boost for late-stage tau-based Alzheimer’ s research. Singapore company TauRx receives $112m investment to take LMTX treatment into phase III. ... These will aim to confirm the benefits of LMTX in reducing progression of Alzheimer's disease.

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics